Sensus

$2.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.03 (+1.04%) Today
+$0.02 (+0.68%) As of 6:25 PM UTC after-hours

Why Robinhood?

You can buy or sell Sensus and other stocks, options, and ETFs commission-free!

About SRTS

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+ and SRT-100 Vision. Its main product, superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL. The listed name for SRTS is Sensus Healthcare, Inc. Common Stock.

CEO
Joseph C. Sardano
Employees
53
Headquarters
Boca Raton, Florida
Founded
2010
Market Cap
48.19M
Price-Earnings Ratio
Dividend Yield
Average Volume
24.27K
High Today
$2.94
Low Today
$2.90
Open Price
$2.90
Volume
2.61K
52 Week High
$4.99
52 Week Low
$1.76

Collections

SRTS Earnings

-$0.22
-$0.13
-$0.03
$0.06
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 11, After Hours

You May Also Like